Pulsenmore Ltd., a pioneer in home ultrasound technology, has announced an expansion of its FDA-authorized home-use prenatal ultrasound devices in the United States. The company is accelerating its growth across the U.S. healthcare system and strengthening engagement with leading medical centers and hospitals nationwide. This expansion coincides with the commencement of trading of Pulsenmore's shares on the Nasdaq Capital Market under the ticker symbol PLSM, which is expected to enhance shareholder value and support the company's growth strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulsenmore Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN67914) on January 21, 2026, and is solely responsible for the information contained therein.